Half-year report · HY
8129.TEDINET S100X3KF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥767.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥1.52T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥755.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥7.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥8.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥20.7bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥9.1bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥19.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.3bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥5.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥754.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥722.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥770.7bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥487.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥465.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥267.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥256.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥262.6bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥96.5bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥89.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥78.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥103.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥128.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥26.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥12.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥99.12 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥313.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.71 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥92.72 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥284.22 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥75.64 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.3% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥30.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥30.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥1.3bn |
| Dispensing Pharmacyreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥49.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥49.5bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2m |
| Dispensing Pharmacyreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥600m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.7bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4.4bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥120m |
| Medical Products Retailreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥739.2bn |
| Medical Products Retailreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥714.2bn |
| Medical Products Retailreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥24.9bn |
| Medical Products Retailreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥7.3bn |
| Other Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.6bn |
| Other Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.8bn |
| Other Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥746m |
| Other Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥475m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥798.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥767.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥30.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥8.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥29.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.3bn |
| Dispensing Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥47.1bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥19m |
| Dispensing Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥18m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.4bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥442m |
| Medical Products Retailreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥728.7bn |
| Medical Products Retailreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥704.3bn |
| Medical Products Retailreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥24.4bn |
| Medical Products Retailreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.0bn |
| Other Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| Other Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Other Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥994m |
| Other Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥203m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥784.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥755.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥29.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥8.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 586
| Item | Context | Value | Unit |
|---|---|---|---|
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | InterimInstant_No1MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No1MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口) | |
| Address major shareholders | InterimInstant_No2MajorShareholdersMember | Original text (Japanese)東京都港区赤坂１－８－１赤坂インターシティＡＩＲ | |
| Name major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)塩野義製薬株式会社 | |
| Address major shareholders | InterimInstant_No3MajorShareholdersMember | Original text (Japanese)大阪府大阪市中央区道修町３－１－８ | |
| Name major shareholders | InterimInstant_No4MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)みずほ証券株式会社 | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)東京都千代田区大手町１－５－１ | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)河野 博行 | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)広島県広島市安佐南区 | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)みずほ信託銀行株式会社 退職給付信託 第一三共口 再信託受託者 株式会社日本カストディ銀行 | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)東京都中央区晴海１－８－12 | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)東邦ホールディングス従業員持株会 | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)東京都世田谷区代沢４－43－11 | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)ＧＯＬＤＭＡＮ，ＳＡＣＨＳ ＆ ＣＯ．ＲＥＧ（常任代理人 ゴールドマン・サックス証券株式会社） | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)２００ ＷＥＳＴ ＳＴＲＥＥＴ ＮＥＷＹＯＲＫ，ＮＹ，ＵＳＡ （東京都港区虎ノ門２－６－１） | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesReciprocalHoldingSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)１単元(100株)未満の株式 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)提出会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |